CHARLES J HOMCY
CIK 1192591 · Chairman of Pharmaceuticals · last filed 2026-06-24
CHARLES J HOMCY is a Chairman of Pharmaceuticals who has filed 97 SEC Form 4 insider transactions across 12 companies since 2007. The most recent filing, for BBIO, was dated Jun 24, 2026. Across all open-market trades the lifetime net is −$51.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $67.7M across reported positions. 32 SEC filings were submitted jointly with BridgeBio Pharma, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$67.67M
12
97
-$51.69M
Filer Profile
C/O BRIDGEBIO PHARMA, INC.
PALO ALTO, CA 94304
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BBIO | Director | 919,876 | $72.44 | $66.64M | -$19.45M | 29 | 2026-06-24 |
| MAZE | Director | 38,535 | $24.60 | $948.0K | $0 | 6 | 2026-06-10 |
| PLRX | Director | — | $1.17 | — | $0 | 1 | 2021-06-30 |
| Population Health Investment Co., Inc. (PHICW) Delisted | Director | — | $0.00 | — | $0 | 1 | 2021-01-26 |
| PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Director | 132,471 | — | — | -$24.66M | 22 | 2019-04-01 |
| Global Blood Therapeutics, Inc. (GBT) Delisted | Director | 84,928 | $68.49 | $5.82M | -$5.09M | 10 | 2018-06-22 |
| MyoKardia, Inc. (MYOK) Delisted | Director | 6,496 | — | — | $0 | 2 | 2016-12-01 |
| CEPHALON INC (CEPH) Delisted | Director | — | — | — | $0 | 3 | 2011-10-17 |
| GERN | Director | 62,751 | $1.35 | $84.7K | $0 | 7 | 2011-05-13 |
| CYTK | Director | — | $73.77 | — | $0 | 3 | 2008-05-27 |
| MILLENNIUM PHARMACEUTICALS INC (MLNM) Delisted | Director | 0 | — | — | -$2.49M | 10 | 2008-05-15 |
| KOSAN BIOSCIENCES INC (KOSN) Delisted | Director | — | — | — | $0 | 1 | 2007-05-30 |
Recent Filings
97 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-24 | BBIO | Grant (A) | +3,990 | $0 | EDGAR |
| 2026-06-23 | BBIO | Tax (F) | −788 | -$52.2K | EDGAR |
| 2026-06-10 | MAZE | Grant (A) | — | $0 | EDGAR |
| 2026-05-06 | MAZE | Gift (G) | −7,422 | $0 | EDGAR |
| 2025-11-21 | MAZE | Other (J) | +1,489 | $0 | EDGAR |
| 2025-10-27 | MAZE | Gift (G) | −28,423 | $0 | EDGAR |
| 2025-09-24 | MAZE | Grant (A) | — | $0 | EDGAR |
| 2025-08-12 | BBIO | Sell (S) | −300,000 | -$13.91M | EDGAR |
| 2025-08-11 | BBIO | Notice (144) | −50,000 | -$2.40M | EDGAR |
| 2025-08-08 | BBIO | Notice (144) | −250,000 | -$11.51M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.